Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Theravance Biopharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will post earnings per share of ($1.01) for the year. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.43) EPS.
Theravance Biopharma Stock Up 2.1 %
Shares of TBPH stock opened at $9.27 on Thursday. The business has a 50 day moving average of $9.34 and a two-hundred day moving average of $8.92. The company has a market cap of $455.84 million, a P/E ratio of -9.18 and a beta of 0.21. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90.
Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million.
Insiders Place Their Bets
In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.90% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Theravance Biopharma
A number of hedge funds have recently made changes to their positions in the business. Aquatic Capital Management LLC bought a new position in Theravance Biopharma in the 4th quarter worth approximately $25,000. Quantbot Technologies LP acquired a new position in Theravance Biopharma during the 3rd quarter worth $60,000. KLP Kapitalforvaltning AS acquired a new position in Theravance Biopharma during the 4th quarter worth $69,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the fourth quarter valued at $103,000. Institutional investors own 99.10% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Read More
Receive News & Ratings for Theravance Biopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Theravance Biopharma and related companies with MarketBeat.com’s FREE daily email newsletter.
